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Vascular endothelial growth factor-A (VEGF) is one of the key regulators of tumor
development, hence it is considered to be an important therapeutic target for cancer
treatment. However, clinical trials have suggested that anti-VEGF monotherapy was less
effective than standard chemotherapy. On the basis of the evidence, we hypothesized that vegf
mRNA may have unrecognized function(s) in cancer cells.
Methods and Findings
Knockdown of VEGF with vegf-targeting small-interfering (si) RNAs increased susceptibility of
human colon cancer cell line (HCT116) to apoptosis caused with 5-fluorouracil, etoposide, or
doxorubicin. Recombinant human VEGF165 did not completely inhibit this apoptosis.
Conversely, overexpression of VEGF165 increased resistance to anti-cancer drug-induced
apoptosis, while an anti-VEGF165-neutralizing antibody did not completely block the resistance.
We prepared plasmids encoding full-length vegf mRNA with mutation of signal sequence, vegf
mRNAs lacking untranslated regions (UTRs), or mutated 59UTRs. Using these plasmids, we
revealed that the 59UTR of vegf mRNA possessed anti-apoptotic activity. The 59UTR-mediated
activity was not affected by a protein synthesis inhibitor, cycloheximide. We established
HCT116 clones stably expressing either the vegf 59UTR or the mutated 59UTR. The clones
expressing the 59UTR, but not the mutated one, showed increased anchorage-independent
growth in vitro and formed progressive tumors when implanted in athymic nude mice.
Microarray and quantitative real-time PCR analyses indicated that the vegf 59UTR-expressing
tumors had up-regulated anti-apoptotic genes, multidrug-resistant genes, and growth-
promoting genes, while pro-apoptotic genes were down-regulated. Notably, expression of
signal transducers and activators of transcription 1 (STAT1) was markedly repressed in the
59UTR-expressing tumors, resulting in down-regulation of a STAT1-responsive cluster of genes
(43 genes). As a result, the tumors did not respond to interferon (IFN)a therapy at all. We
showed that stable silencing of endogenous vegf mRNA in HCT116 cells enhanced both STAT1
expression and IFNa responses.
Conclusions
These findings suggest that cancer cells have a survival system that is regulated by vegf
mRNA and imply that both vegf mRNA and its protein may synergistically promote the
malignancy of tumor cells. Therefore, combination of anti-vegf transcript strategies, such as
siRNA-based gene silencing, with anti-VEGF antibody treatment may improve anti-cancer
therapies that target VEGF.
The Editors’ Summary of this article follows the references.
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Vascular endothelial growth factor-A (VEGF) is one of the
key regulators in tumor formation and progression [1–4]. The
clinical signiﬁcance of VEGF in tumors has been demon-
strated by many studies showing that the VEGF expression
level is correlated with tumor grade, depth of invasion, status
of nodal and distant metastasis, and clinical stage [5–10]. In
addition, high levels of circulating VEGF are associated with
resistance to chemotherapy in patients with metastatic solid
tumors, including colorectal cancer [11,12]. The stimulatory
action of VEGF on tumor angiogenesis is believed to play a
central role in promotion of tumor development. At the same
time, VEGF is known to act as an autocrine survival and
growth factor for tumor cells [13]. Based on the evidence
outlined above, a number of strategies to target VEGF or
VEGF receptors (VEGFR) have been developed and subjected
to clinical evaluation [14]. In contrast to preclinical studies in
animal models, clinical trials suggest that anti-VEGF mono-
therapy was less effective than standard chemotherapy [15],
raising the possibility that VEGF or possibly vegf mRNA might
possess unrecognized function(s).
A recent report has shown that VEGF protein functions as
an internal autocrine survival factor in human breast cancer
cells through internally expressed VEGFR [16]. In addition,
non-coding RNAs have now been recognized to play critical
roles in tumorigenesis [17]. One class of the tumor-associated
non-coding RNAs is the untranslated region (UTR) of certain
mRNAs, including the 39UTR of a-tropomyosin mRNA [18], the
39UTR of prohibitin mRNA [19], the 39UTR of ribonucleotide
reductase mRNA [20], and the 59UTR of c-myc mRNA [21]. All of
these UTR RNAs function as tumor suppressors. From this
point of view, we directed our attention to a unique structure
of vegf mRNA characterized by its unusually long 59UTR
(1,038 nucleotide [nt]) containing two internal ribosome
entry sites (IRES) [22,23].
Methods
Reagents
Recombinant human (rh) interferon alpha (IFNa) was
purchased from PBL Biomedical Laboratories. rhIFNc,
rhVEGF165, and anti-VEGF165-neutralizing monoclonal anti-
body (Ab) were from R&D Systems.
Cell Culture and Transfection
The human colon carcinoma cell lines (HCT116 and RKO)
were maintained in McCoy’s 5A medium, supplemented with
10% (v/v) FCS and antibiotics. The human embryonic kidney
cell line (HEK293) was maintained in DMEM medium,
supplemented with 10% (v/v) FCS and antibiotics. The human
gastric carcinoma cell line (AGS) was maintained in F-12
medium, supplemented with 10% (v/v) FCS and antibiotics.
Amounts of VEGF165 secreted into the culture medium were
measured by ELISA assay (Quantikine, R&D Systems),
according to the manufacturer’s instructions.
Transfection of cells was performed using the jetPEI
(Polyplus-transfection) or FuGENE HD (Roche Diagnostics)
transfection reagent, according to the manufacturer’s in-
structions. We checked the transfection efﬁciency by mon-
itoring expression of yellow ﬂuorescent protein (YFP)-
expressing plasmid and determined the efﬁciency to be
60%–65% in HCT116 cells, 80%–85% in HEK293 cells, 60%–
65% in RKO cells, and 60%–65% in AGS cells.
Cell Growth
Cell growth was assessed using a CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega), according to the
manufacturer’s instructions. Cells were plated in a 96-well
ﬂat-bottom plate and cultured in 100 ll of McCoy’s 5A
medium containing 10% (v/v) FCS and antibiotics, and the
MTT reagent (20 ll/well) was added to each well and
incubated for 1 h. The levels of blue formazan were measured
spectrophotometrically at 490 nm at each time point using a
microplate reader (Wallac 1420 ARVO MX; Perkin Elmer).
To assess anchorage-independent growth, cells (1 3 10
5)
were plated in 2 ml of McCoy’s 5A medium containing 10%
(v/v) FCS and 0.33% agar. This suspension was layered over a
3-ml base layer of solidiﬁed McCoy’s medium containing 10%
(v/v) FCS and 0.5% agar in 60-mm diameter culture dishes.
Following a 28-d incubation at 37 8Ci n5 %C O 2, the number
of colonies (approximately .0.1 mm in diameter) with dense
centers was scored for each plate.
Assessment of Apoptosis
Apoptotic cells were assessed by the TUNEL-staining
method using an in situ Cell Death Detection kit (Roche
Diagnostics). TUNEL-positive cells were viewed using a
microscope, and percentages of the positive cells were
calculated. A minimum of 300 cells was counted for each
determination. Apoptosis was also detected using the
APOPercentage apoptosis assay kit (Biocolor), according to
the manufacturer’s instructions. The APOPercentage dye
stains cells undergoing the membrane ‘‘ﬂip-ﬂop’’ event when
phosphatidylserine is translocated to the outer leaﬂet. This
event is speciﬁc for apoptosis, but not for necrosis.
The caspase 3/7 activity was measured using the Caspase-
Glo 3/7 assay (Promega), according to the manufacturer’s
instructions. After cells were treated with 80 lMo f5 -
ﬂuorouracil (5-FU) for 24 h, the Caspase-Glo 3/7 reagent was
added to each well and incubated for 1 h. The luminescence
was measured using a microplate-reading luminometer
(Wallac 1420 ARVO MX; Perkin Elmer).
Plasmid Constructions and Establishment of Stable
Transfectants
The plasmids expressing vegf small-interfering RNAs
(siRNAs) were constructed using a BLOCK-iT Pol II miR
RNAi expression vector kit (Invitrogen), in accordance with
the manufacturer’s protocol. A pcDNA6.2-GW/EmGFP-miR-
NA vector that contains the GFP-coding region within the
pre-miRNA expression cassette was inserted with the follow-
ing pairs of sense and antisense DNA: vegf siRNA number 1,
59-TGC TGA GCA AGG CAA GGC TCC AAT GCG TTT TGG
CCA CTG ACT GAC GCA TTG GAC TTG CCT TGC T-39
(sense) and 59-AGC AAG GCA AGT CCA ATG CGT CAG
TCA GTG GCC AAA ACG CAT TGG AGC CTT GCC TTG
CTC AGC A-39 (antisense); vegf siRNA number 2, 59-TGC TGA
GAG CAG CAA GGC AAG GCT CCG TTT TGG CCA CTG
ACT GAC GGA GCC TTC TTG CTG CTC T-39 (sense) and 59-
AGA GCA GCA AGA AGG CTC CGT CAG TCA GTG GCC
AAA ACG GAG CCT TGC CTT GCT GCT CTC AGC A-39
(antisense). These siRNAs were cloned into pcDNA6.2-GW/
EmGFP-miRNA vector (siVEGF#1 and siVEGF#2 in Figure 1).
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pcDNA6.2-GW/EmGFP-miR-negative control plasmid ex-
pressing mature siRNA that is predicted not to target any
known vertebrate genes (Invitrogen).
The following plasmid constructs were kindly provided by
Drs. Herve ´ Prats and Anne-Catherine Prats [24–27]:
pAUG165mSPHA (construct I in Figure 2A), p165mSPHA 39
(construct II), pVC (construct V), pSCT-chloramphenicol
acetyltransferase (CAT) (construct IX), pVCTTT (construct
XI), the plasmids expressing a chimeric mRNA fused to CAT
coding sequence comprising one of the constructs (the
human bip 59UTR, the human c-myc 59UTR, the human fgf-2
59UTR, and the human pdgf-b 59UTR), and the bicistronic
plasmid contains two luciferase genes, Renilla luciferase
(LucR) and ﬁreﬂy luciferase (LucF), which are separated by
a hairpin (hairpin control) or an IRES of human bip (pRBL),
human c-myc (pRMyP2L), and human fgf-2 (pRFL).
p165mSPHA 39 and p165AUGmSPHA have H9D and L14E
mutations in the signal sequence that prevent secretion of the
VEGF165 protein. p165mSPHA 39 was digested with ClaI and
ApaI, blunted by Klenow treatment, and religated. The resulting
plasmid (p165mSPHA,constructIIIin Figure2A) didnotcontain
the 39UTR sequence. p165mSPHA 39 was digested with XbaI and
NgoMIV, blunted by Klenow treatment, and religated. The
resulting plasmid (pAUG165mSPHA 39,c o n s t r u c tI V )d i dn o t
encode the 59UTR sequence. Several deletion constructs of the
vegf 59UTR were also made from the pVC plasmid by digestion
with NgOMIV (construct VI), XbaI and NheI (construct VII), or
BamHI (construct VIII). We also prepared a plasmid encoding
full-lengthvegfmRNAwithanintactsignalpeptidesequence.The
construct pVC, which has an intact signal sequence, was digested
with NarI and BsaBI, and the resultant NarI-BsaBI fragment was
ligated into p165mSPHA 39 to reconstruct full-length vegf mRNA
with an intact signal peptide sequence (p165HA 39). A construct
mutated between nt 591 and nt 746 of the vegf 59UTR was
synthesized using two serial double-stranded DNA fragments
(mutations are indicated by lower case letters): nt 576 -GCG AGC
CGC GGG CAa GGa CCa GAa CCa GCa CCa GGg GGa GGa GTa
GAaGGaGTaGGGGCTC-nt636andnt637-GGGCTCGaGGa
GTa GCa tta AAg CTa TTt GTa CAg tta tta GGa TGc TCa CGa
TTt GGg GGg GCa GTa GTa aga GCa GGa GAg GCa GAa CCa
AGt GGg GCa GCa AGg AGT GCT AGC- nt 752. The two
synthesized fragments were ligated and inserted into pVC
digested with SacII and NheI to generate plasmid pVCmut
(construct X in Figure 2A). All the constructs were conﬁrmed to
have the expected sequences using a DNA sequencer. The
secondary structures of vegf 59UTR and its mutant were analyzed
using the mfold 3.2 algorithm of Zuker [28].
We also constructed a plasmid expressing a chimeric mRNA
comprising the vegf 59UTR fused to YFP. The constructs pVC
and pVCmut were digested with EcoRI and NcoI, and the
resulting EcoRI-NcoI fragments were ligated into pd2EYFP-
N1 (Clontech) to generate pVY and pVYmut, respectively.
Stable transfectants were constructed using early passages
of HCT116 cells that had been plated at approximately 1 3
10
5 in a 60-mm diameter culture dish and cultured overnight.
The cells were transfected with 5 lg of pYFP, pVY, pVYmut,
siVEGF#1, or pcDNA6.2-GW/EmGFP-miRNA-neg control
plasmids. Clones were selected and maintained in McCoy’s
5A medium supplemented with 450 lg/ml G418 (Invitrogen),
or with 5 lg/ml Blasticidin (Invitrogen). Three stably trans-
fected cell lines (HCT116/YFP, HCT116/vegf 59, HCT116/vegf
Figure 1. Effect of vegf Transcript on Susceptibility to Anti-Cancer Drugs
(A) Knockdown efficiency of vegf mRNA. Expression levels of vegf mRNA
were measured using quantitative RT-PCR. Values were normalized for
the amount of gapdh mRNA (means 6 SEM, n ¼ 4).
(B) Knockdown of vegf mRNA increases 5-FU induced apoptosis. Cells
untransfected ( ) or transfected with the indicated plasmids for 24 h were
treated with 20 lM 5-FU or rhVEGF protein (1, 2, 4, or 6 ng/ml) combined
with 5-FU (20 lM) for 48 h. Apoptosis was evaluated by calculating the
percentages of TUNEL-positive cells. Values are means 6 SEM from four
independent experiments. Means with different superscripts are signifi-
cantly different by ANOVA followed by Scheffe ´’s test (p , 0.05).
(C) Overexpression of vegf transcript induces resistance to 5-FU. Cells
were transfected with a plasmid encoding full-length vegf mRNA or an
empty vector (mock) for 24 h. The cells were treated without or with 80
lM 5-FU in the presence of a monoclonal anti-human VEGF165-
neutralizing Ab at the indicated concentrations for 48 h, and then
apoptotic cells were identified and quantitated by the TUNEL-staining
method. Values are means 6 SEM from three independent experiments.
Means with different superscripts are significantly different by ANOVA
followed by Scheffe ´’s test (p , 0.05).
doi:10.1371/journal.pmed.0050094.g001
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after 28 d of selection.
Western and Northern Blot Analyses
Cell lysates were prepared using a lysis buffer containing
100 mM Tris-HCl (pH 6.8), 300 mM NaCl, 2 mM EDTA, and
4% (v/v) SDS. Western immunoblotting was performed as
described previously [29] using a rabbit polyclonal anti-
human inﬂuenza virus hemagglutinin (HA) Ab (Santa Cruz
Biotechnology) at a 1/1,000 dilution, a mouse monoclonal Ab
against human signal transducers and activators of tran-
scription 1 (STAT1) (Cell Signaling) at a 1/1,000 dilution, a
Figure 2. Effects of vegf 59UTR RNA on Resistance to 5-FU
(A) Schematic of the constructs transfected into HCT116 cells. mSP, mutated signal peptide; HA, hemagglutinin.
(B) The vegf 59UTR induces 5-FU resistance. Cells untransfected ( ) or transfected with the indicated construct for 24 h were treated with 80 lM 5-FU for
48 h, and then apoptotic cells were identified and quantitated by the TUNEL-staining method. Values are means 6 SEM from three independent
experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe ´’s test (p , 0.05).
(C) Determination of functional element in the vegf 59UTR. Cells untransfected ( ) or transfected with the indicated construct for 24 h were treated with
80 lM 5-FU for 48 h. Apoptotic cells was then measured by the TUNEL-staining method as described above. Values are means 6 SEM from three
independent experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe ´’s test (p , 0.05).
(D) The vegf 59UTR-mediated resistance to 5-FU is independent of de novo protein synthesis. Cells transfected with the indicated plasmids for 24 h were
treated with 80 lM 5-FU in the absence or presence of CHX (1 or 10 lg/ml) for 40 h. Apoptosis was assessed by the TUNEL-staining method. Values are
means 6 SEM from four independent experiments. Means with different superscripts are significantly different by ANOVA followed by Scheffe ´’s test (p
, 0.05).
doi:10.1371/journal.pmed.0050094.g002
PLoS Medicine | www.plosmedicine.org May 2008 | Volume 5 | Issue 5 | e94 0808
Tumor Progression by vegf mRNArabbit polyclonal anti-L-VEGF Ab at a 1/500 dilution (a gift
from Herve ´ Prats) [26], or a mouse anti-b-actin monoclonal
Ab (Sigma). The speciﬁcity of individual antibody reactivity
was conﬁrmed by the absorption test with the corresponding
antigen peptide (Figure S10). Blocking antigen peptide for
human STAT1 and HA were obtained from Cell Signaling
and Santa Cruz Biotechnology, respectively. Antigen peptides
for L-VEGF were synthesized using an Applied Biosystems
432A peptide synthesizer.
Total RNA was prepared by the guanidinium thiocyanate
method. Northern hybridization was performed as described
previously [29] using following cDNA probes. cDNA probes
for vegf 59UTR RNA and vegf ORF RNA were prepared by
digestion of the plasmid p165mSPHA 39 with NgoMIV and
ClaI, and SacII and NheI, respectively. A cDNA probe for
CAT mRNA was prepared as a digestion fragment of the
plasmid pVC using EcoRI and BglII sites. These probes were
labeled with [a-
32P]dCTP using Klenow enzyme (New England
BioLabs), according to the manufacturer’s instructions.
Animal Studies and Immunohistochemistry
The use of animals in the experiments described here was
approved by the Animal Care Committee of University of
Tokushima. Seven-wk-old male athymic nude mice (Nippon
SLC) were caged in groups of ﬁve and acclimated for 1 wk. A
cell suspension (5 3 10
6 cells) in serum-free McCoy’s 5A
medium, prepared from each stably transfected clone, was
injected subcutaneously into the ﬂanks of nude mice. The
sizes of tumors that developed in the injected mice were
measured in two dimensions with a caliper and their volumes
calculated using the formula (L3W
2)30.5, where L is length
and W is width. We conﬁrmed that parental HCT116 cells (5
3 10
6 cells) injected subcutaneously into nude mice formed
tumors whose volumes were around 500 mm
3 day 28 after
transplantation. Therefore, HCT116/YFP clones appeared to
form xenograft tumors less efﬁciently than parental HCT116
cells, probably because expression of YFP and/or procedures
during the establishment of permanent cell cloning was likely
to nonspeciﬁcally reduce the tumor-forming capability.
Some mice were injected intraperitoneally with BrdU (1.5
g/kg body weight, Sigma-Aldrich) 2 h before they were
humanely killed. The mice were killed on the indicated days,
and growing tumors were removed and ﬁxed with formalin in
PBS. The ﬁxed xenografts were sectioned and stained with
hematoxylin and eosin (HE), or by immunohistochemistry
using a mouse monoclonal anti-BrdU Ab (Sigma-Aldrich), or
by a DeadEnd colorimetric TUNEL System (Promega).
Vasculature was stained using a rat anti-mouse CD31 Ab
(BD Pharmingen).
We also examined the effects of 5-FU on implanted tumors.
In this experiment, HCT116/vegf 59 transfectants (5 3 10
6
cells) were injected subcutaneously into the left ﬂanks of nude
mice, and HCT116/YFP (1 3 10
7 cells) or HCT116/vegf 59mut
transfectants (1310
7 cells) were injected into the right ﬂanks
of the same mice. When the tumors reached a size of
approximately 40 mm
3, usually by day 7, the mice were
treated daily with an intraperitoneal injection of 5-FU (30
mg/kg weight, Sigma-Aldrich), or with 5-FU (30 mg/kg weight)
plus IFNa (50,000 U/mouse; PBL Biomedical Laboratories).
The tumor sizes were measured daily using a caliper, and
their volumes were calculated as described above.
Microarray Analysis
We used Agilent Human 1A oligomicroarrays (Agilent
Technologies) containing 60-mer DNA probes synthesized in
situ in a 22-k format. Total RNA was prepared from three
independent vegf 59-G5 tumors on day 14, and an equal
amount of RNA from each tumor was mixed. After
contaminating DNA had been removed using a DNase kit
(Qiagen), the resultant RNA quality was evaluated using the
Agilent 2100 Bioanalyzer (Agilent Technologies). Total RNA
was also prepared from three vegf 59mut-D5 tumors on day 14
in the same manner. Synthesis, ampliﬁcation, and labeling of
cRNA were carried out in accordance with the manufac-
turer’s protocol. Cy5-cRNA (0.75 lg) prepared from vegf 59-G5
tumors was mixed with the same amount of Cy3-cRNA from
vegf 59mut-D5 tumors. Hybridization was performed on the
Agilent Human 1A oligomicroarray (Agilent Technologies),
according to the manufacturer’s protocol. Fluorescence
images of the hybridized microarrays were obtained using
an Agilent microarray scanner (G2565BA). Signal intensities
of Cy5 and Cy3 were quantiﬁed and analyzed by subtracting
the backgrounds using feature extraction software (Agilent,
version 9.5). The Cy5/Cy3 ratios of 12,178 genes that had a
higher ﬂuorescence value than 100 for both Cy5 and Cy3
signals were transformed to logarithms for global normal-
ization. We selected genes whose mRNA levels differed by .2-
fold between vegf 59-G5 and mut-D5 tumors.
Dual-Luciferase Assay
To measure IRES activity, we used the bicistronic plasmid.
The bicistronic cassette expresses the LucR in a cap-depend-
ent manner and LucF in an IRES-dependent manner. Each
IRES or hairpin control is located between the two cistrons.
To measure IFN-dependent transcriptional activity, we
used plasmids containing the motifs IFN-stimulated regula-
tory element (ISRE) and IFN-c-activated sequence (GAS)
upstream of the LucF reporter gene (Pathway Proﬁling
Luciferase System).
LucF and LucR activities were measured using the Dual-
Luciferase reporter assay system (Promega), according to the
manufacturer’s instructions. Transfected cells were rinsed
twice with PBS, scraped, and homogenized in 50 ll of lysis
reagent provided with the kit. The lysate was cleared by a 2-
min centrifugation at 4 8C. Chemiluminescent signals were
measured in a luminometer (Wallac 1420 ARVO MX; Perkin
Elmer) equipped with automatic injectors.
Quantitative Real-Time PCR
SuperScript II RNase H-reverse transcriptase (Invitrogen)
was used to synthesize cDNAs from 1 lg aliquots of total RNA
prepared from three independent tumor tissues. Taqman
Gene Expression assays (Applied Biosystems) were used with
the following cDNA-speciﬁc primers and probes: mia
(Hs00197954_m1); bcl6 (Hs00153368_m1); egfr
(Hs00193306_m1); nrg1 (Hs00247624_m1); pcdc1
(Hs00169472_m1); fas (Hs00531110_m1); bax
(Hs00180269_m1); xaf1 (Hs00213882_m1); trail/apo2
(Hs00234356_m1); nmi (Hs00190768_m1); isg20
(Hs00158122_m1); oas1 (Hs00242943_m1); oas2
(Hs00213443_m1); irf1 (Hs00233698_m1); pml
(Hs00231241_m1); and gapdh (Hs99999905_m1). The levels
of transcripts for IFN receptors (ifnar1, ifnar2, ifngr1, and
ifngr2), VEGF receptors (vegfr1, vegfr2, nrp1 and nrp2), stat1,
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the following speciﬁc primer sets: ifnar1,5 9-CCC AGT GTG
TCT TTC CTC AAA-39 (forward) and 59-AAG ACT GGA GGA
AGT AGG AAA GC-39 (reverse); ifnar2,5 9-AGT CAG AGG
GAA TTG TTA AGA AGC A-39 (forward) and 59-TTT GGA
ATT AAC TTG TCA ATG ATA TAG GTG-39 (reverse); ifngr1,
59-GGT GTG AGC AGG GCT GAG-39 (forward) and 59-GTA
ACA TTA GTT GGT GTA GGC ACT G-39 (reverse); ifngr2,5 9-
GGC CTG ATT AAA TAC TGG TTT CA-39 (forward) and 59-
GGG CTG AGT TGG GTC TTT TA-39 (reverse); vegfr1,5 9-
AGA ACC CCG ATT ATG TGA GAA A-39 (forward) and 59-
GAT AGA TTC GGG AGC CAT CC-39 (reverse); vegfr2,5 9-
GAA CAT TTG GGA AAT CTC TTG C-39 (forward) and 59-
CGG AAG AAC AAT GTA GTC TTT GC-39 (reverse); nrp1,5 9-
CCC TGA GAA TGG GTG GAC T-39 (forward) and 59-CGT
GAC AAA GCG CAG AAG-39 (reverse); nrp2,5 9-GGA CCC
CCA ACT TGG ATT-39 (forward) and 59-ATG GTT AAA AAG
CGC AGG TC-39 (reverse); stat1,5 9-CTG CTC CTT TGG TTG
AAT CC-39 (forward) and 59-GCT GAA GTT CGT ACC ACT
GAG A-39 (reverse); vegf,5 9-GAG CCT TGC CTT GCT GCT
CTA C-39 (forward) and 59-CAC CAG GGT CTC GAT TGG
ATG-39 (reverse); b-actin, 59-CCA ACC GCG AGA AGA TGA-
39 (forward) and 59-CCA GAG GCG TAC AGG GAT AG-39
(reverse). Ampliﬁcation and quantiﬁcation of the PCR
products were performed using the Applied Biosystems
7500 System (Applied Biosystems). Standards were run in
the same plate and the relative standard curve method was
used to calculate the relative mRNA expression. RNA
amounts were normalized against the gapdh mRNA level.
Statistical Analysis
The data were analyzed using the two-tailed Student’s t-test
or ANOVA and the Scheffe ´’s test. A p-value of less than 0.05
was considered signiﬁcant.
Results
Effect of vegf mRNA on Apoptosis Caused with Anti-
Cancer Drugs
First, we investigated whether vegf mRNA possessed a
tumor-promoting activity in HCT116 cells that expressed
VEGFR-2 and Neuropilin-1,  2 (Figure S6) and secreted
spontaneously VEGF165 at 759 6 32 pg/ml (mean 6 SD, n¼4).
Two different vegf-targeting siRNAs successfully knocked
down endogenous vegf mRNA in HCT116 cells (Figure 1A).
This silencing made the cells susceptible to apoptosis caused
with a low concentration of 5-FU (20 lM). We then examined
the effect of supplementation of rhVEGF165 in the knock-
down cells. The amount of secreted VEGF165 increased to
1,018 6 48 (n ¼4) from the cells that were untransfected and
treated with 5-FU (20 lM) for 48 h. An external supplemen-
tation of 1,000 pg/ml rhVEGF165 failed to block the 5-FU-
induced apoptosis in vegf siRNA-transfected cells (Figure 1B).
Treatment with rhVEGF165 at 2,000 pg/ml or higher signiﬁ-
cantly, but not completely, prevented the apoptosis.
In contrast, cells were transiently transfected with a
plasmid expressing full-length vegf165 mRNA and exposed to
a higher concentration of 5-FU (80 lM). These cells secreted
VEGF165 (7,092 6 23 pg/ml, n ¼ 4) during the experimental
period and exhibited resistance to 5-FU-induced apoptosis
(Figure 1C). It should be noted that anti-VEGF165-neutralizing
monoclonal Ab could not completely cancel the anti-
apoptotic activity even at concentrations of up to 5 lg/ml
(about 250 molar excess amount of secreted VEGF165) (Figure
1C). Both knockdown and overexpression experiments
suggest that both VEGF protein and vegf mRNA may possess
an anti-apoptotic function. Similar or even clearer results
were observed in the cells treated with other anti-cancer
drugs, etoposide and doxorubicin (Figure S1A and S1B).
Effect of vegf mRNA 59UTR on Apoptosis Caused by 5-FU
Next, we used the mutated full-length vegf165 mRNA-
expressing plasmid that has mutations of two amino acid
residues within the signal peptide, shown as ‘‘mSP’’ in
construct II (Figure 2A). This plasmid-derived mRNA is
translated into a nonsecreted VEGF165 protein [26]. We
conﬁrmed that cells transfected with this construct expressed
full-length vegf mRNA and VEGF165 protein (Figure S2A), but
did not secrete detectable amounts of the plasmid-derived
VEGF165 (unpublished data). As was described above, HCT116
cells overexpressing full-length vegf165 mRNA without muta-
tion were completely resistant to 80 lM 5-FU (Figure 1C). In
contrast, cells transfected with construct II signiﬁcantly, but
not completely, blocked the 5-FU-induced apoptosis (Figure
2B and Figure S3A). This partial loss of anti-apoptotic activity
was probably due to the lack of VEGF165-secreting activity.
Next, we prepared the constructs lacking the 39UTR (con-
struct III), 59UTR (construct IV), or both (construct I), and
found that the 59UTR was associated with the chemoresistant
phenotype (Figure 2B). Similar results were observed in the
cells treated with other anti-cancer drugs, etoposide and
doxorubicin (Figure S1C and S1D).
To conﬁrm the functional role of the 59UTR, we used a
plasmid expressing the vegf 59UTR fused to CAT coding gene
(Figure 2A, construct V), which does not express VEGF
protein. This chimeric mRNA retained the resistance to 5-FU
(Figure 2C). We then designed several deletion constructs of
the chimeric mRNA (constructs VI–VIII in Figure 2A), and
found that the 270-nt-long element delimited by positions nt
475 and nt 745 in the 59UTR sequence was crucial for the
drug-resistance phenotype (Figure 2C). This sequence is just
upstream of IRES-A, but does not require the IRES activity
[22].
It is known that the 59UTR of human vegf mRNA encodes
long N-terminal VEGF proteins (termed L-VEGF) that are
translated from CUG codons upstream of and in-frame with
the classical AUG start codon [24]. To eliminate the
possibility that the L-VEGF proteins might induce the
chemoresistance, we designed a mutated 59UTR construct
that produced L-VEGF protein, but modiﬁed the RNA
structure by substituting the nucleic acid sequence between
nt 591 and nt 746 (construct X in Figure 2A). Secondary
structures of the vegf 59UTR and its mutated 59UTR were
predicted by mFold program (Figure S5). The mutation
changed the secondary structure of several parts and ablated
a stem-loop structure that is located in the functional region
of the vegf 59UTR (nt 699 to nt 738) as described above. The
mutated construct X produced L-VEGF protein (Figure S2B),
but did not induce the resistance to 5-FU (Figure 2C). We also
used a simply mutated 59UTR, in which the ﬁrst CUG codon
was substituted into a noninitiating UUU codon (construct XI
in Figure 2A) [24]. This mutant did not produce L-VEGF
protein (Figure S2B), but was able to induce the resistance as
efﬁciently as did the wild-type 59UTR (Figure 2C). We further
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heximide (CHX). To determine the inhibitory effect of CHX,
HCT116 cells were transfected with plasmid encoding
luciferase in the absence or presence of CHX, and luciferase
activity was measured. Protein synthesis was blocked by 86 6
5% (mean 6 SD, n¼3) and 94 6 3% (mean 6 SD, n¼3) with
1 and 10 lg/ml CHX, respectively. As shown in Figure 2D,
both full-length vegf mRNA (construct II) and vegf 59UTR-CAT
mRNA (construct V) efﬁciently inhibited 5-FU-induced
apoptosis even in the presence with 10 lg/ml CHX. These
results suggest that the 59UTR-mediated chemoresistance
may not require de novo protein synthesis.
In addition to the TUNEL-staining method, we evaluated
the vegf 59UTR-mediated anti-apoptotic effect by the Apo-
percentage-staining method (Figure S3C) and by measuring
activities of caspase 3 and caspase 7 (Figure S3D), which are
crucial effector enzymes for apoptosis induced by genotoxic
agents. We conﬁrmed that the results obtained by the
Apopercentage-staining method were similar to those by
the TUNEL assay (Figure S3B and S3C). Cells transfected with
construct II, V, and XI signiﬁcantly, but not completely,
blocked the activation of caspase 3/7 (Figure S3D).
To examine whether this anti-apoptotic function is
peculiar to vegf mRNA 59UTR, we used three 59UTRs
containing IRES (c-myc, bip, and fgf-2 mRNA 59UTRs) [30]
and the pdgf-b mRNA 59UTR that is unusually long, but does
not contain IRES activity [31]. After transfection with plasmid
expressing one of the indicated 59UTR-CAT mRNAs, apop-
tosis was assessed by the TUNEL-staining method. Only the
vegf 59UTR induced the resistance to 5-FU among 59UTRs
tested (Figure S4).
We also examined whether the vegf 59UTR similarly induce
the chemoresistance in other human cancer cell lines (RKO,
HEK293, and AGS cells), and conﬁrmed that both full-length
vegf mRNA and vegf 59UTR RNA induced 5-FU resistance in
these cells. (Figure S6B–S6D). These observations suggest that
the vegf 59UTR function is not peculiar to HCT116 cells.
The vegf 59UTR contains IRES sequences that interact with
IRES-binding factors and regulate translation initiation in a
cap-independent manner [22,23]. Many IRES-containing
mRNAs encode proteins that regulate cell growth, differ-
entiation, and apoptosis [30,32]. Thus, overexpression of the
vegf 59UTR raises the possibility that increased amounts of the
vegf 59UTR may trap IRES-binding factors, thereby non-
speciﬁcally modifying IRES-dependent expression of genes.
To address this issue, we tested the effect of vegf 59UTR on
other IRES activities (Figure S7B). HCT116 cells were
cotransfected with plasmids expressing vegf 59UTR-CAT
mRNA (construct V or mutated construct X in Figure 2A)
and the bicistronic construct containing 59UTR of the
indicated genes. We conﬁrmed that overexpression of the
vegf 59UTR RNA did not repress the IRES activity of bip, c-myc,
or fgf-2 59UTR (Figure S7B).
Characterization of HCT116 Cells Stably Expressing vegf
59UTR
To investigate chronic effects of the vegf mRNA 59UTR on
malignant transformation of HCT116 cells both in vitro and
in vivo, we established stable transfectants that expressed
chimeric mRNAs of either the vegf 59UTR or the mutant one
(as described above) fused to the YFP coding gene. Use of
these chimeric mRNAs had the following advantages: (i) they
did not produce VEGF protein, (ii) expression of these
elements could be monitored by YFP ﬂuorescence, and (iii)
the chimeric mRNAs were translated similarly as vegf mRNA
in our cell system. Ectopic mRNAs were equally expressed in
corresponding cell lines and did not modify the amounts of
endogenous vegf mRNA and VEGF among the clones (Figure
S8A and S8B).
The vegf 59UTR-expressing cells (HCT116/vegf 59, clones G3
and G5) were again resistant to 5-FU-induced apoptosis
(Figure 3A). In contrast, the mutant vegf 59UTR-expressing
cells (HCT116/vegf 59mut, clones D5 and E4) or the trans-
fection control cells (HCT116/YFP, clone G11) underwent
apoptosis by 5-FU (Figure 3A). We also examined the growth
rate of each clone and observed that the HCT116/vegf 59
exhibited a small, albeit signiﬁcant increase in growth rate
compared to the HCT116/vegf 59mut and the control HCT116/
YFP (Figure 3B). Furthermore, HCT116/vegf 59 displayed a
distinctive, anchorage-independent growth, while HCT116/
vegf 59mut and the control HCT116/YFP did not (Figure 3C
and 3D).
Tumor-Forming Activity of the HCT116/vegf 59 Clones
To demonstrate the malignancy of HCT116/vegf 59 in vivo,
athymic nude mice were injected subcutaneously with each
clone, and growing tumor masses were measured. Both
HCT116/vegf 59mut and control HCT116/YFP formed small
tumor masses that did not expand further (vegf 59mut-tumor
and YFP-tumor, respectively). In contrast, HCT116/vegf 59
rapidly and progressively formed tumors (vegf 59-tumor). The
average volumes of the vegf 59-tumors were 4-fold and 41-fold
larger than those of the control YFP-tumors on days 5 and 28,
respectively (Figure 4B). There was no signiﬁcant difference
between the sizes of tumors derived from vegf 59-G3 clone and
-G5 clone at either time point.
Histological examination showed that the growing vegf 59-
tumors contained central necrotic areas, while the vegf 59mut-
tumors formed a small nest of tumors encapsulated by
connective tissue (Figure 4C). We next tested whether the
accelerated growth of the vegf 59-tumors was a consequence of
enhanced proliferation, decreased apoptosis, or both. Apop-
tosis and proliferation were assessed by quantifying TUNEL-
positive and BrdU-incorporating cells, respectively (Figure
4C). The vegf 59-tumors showed a small, but signiﬁcant
increase in the numbers of BrdU-positive cells (Figure 4D)
compared with the vegf 59mut-tumors. The number of
apoptotic cells in the vegf 59-tumor was signiﬁcantly lower
than in the vegf 59mut-tumor (Figure 4D). These results
suggest that the vegf 59UTR RNA may accelerate tumor
growth by suppression of apoptosis and promotion of cell
growth. We also examined the development of tumor vessels
by staining with an Ab against an endothelial cell marker
CD31. The vegf 59-tumors signiﬁcantly increased CD31-
positive microvessels (Figure 4C) in association with enlarge-
ment of the tumors, compared with the vegf 59mut-tumors.
Changes in Gene Expression in the vegf 59-Tumors
Total RNA was prepared on day 14 from three different
vegf 59-tumors, and an equal amount of RNA from each tumor
was mixed. Total RNA was also prepared from three different
vegf 59mut-tumors in the same manner. Using a microarray
technique, gene expression proﬁles were compared between
the two RNA samples. The vegf 59-tumors up-regulated mRNA
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fold, compared with the vegf 59mut-tumors (see gene lists in
Tables S1 and S2). One of the distinctive identifying features
of the listed genes was that the vegf 59-tumors selectively
down-regulated pro-apoptotic genes (eight genes) and up-
regulated anti-apoptotic genes (ﬁve genes). Quantitative RT-
PCR validated the signiﬁcant up-regulation of an anti-
apoptotic gene (mia) and down-regulation of pro-apoptotic
genes (fas, pcdc1, nrg1, and bax) (Table 1).
It should also be noted that a major set of IFN-inducible
genes (43 genes) were speciﬁcally down-regulated in the vegf
59-tumors (Table 2), whereas none of IFN-inducible genes
were included in the up-regulated genes (Table S1). Using
quantitative RT-PCR, we compared mRNA levels of nine IFN-
inducible genes between the vegf 59-tumors and the vegf
59mut-tumors, and validated signiﬁcant down-regulation of
eight out of nine genes in the vegf 59-tumors (Table 1). An
IFN-inducible gene stat1 encoding a critical transcription
Figure 3. Characterization of HCT116 Cells Stably Expressing the vegf 59UTR RNA
(A) 5-FU resistance in stable transfectant expressing the vegf 59UTR RNA. Stably transfected HCT116 clones (HCT116/YFP-G11, HCT116/vegf 59-G3,
HCT116/vegf 59-G5, HCT116/vegf 59mut-D5, and HCT116/vegf 59mut-E4) were treated with 80 lM 5-FU for the indicated time, and then apoptotic cells
were identified and quantitated by the TUNEL-staining method. Values are means 6 SEM from three independent experiments.
(B) Growth rate of the stable transfectants. Cell growth was assessed by MTT assay at the indicated time points. Results are expressed as relative
increases in the absorbance, compared with that at time 0. Values are means 6 SEM, n ¼ 4.
(C and D) Increase in anchorage-independent growth ability in the vegf 59UTR-expressing clones. The stably transfected clones were cultured in semi-
solid medium for 28 d as described in the Methods. Pictures of growing colonies on day 28 are shown in (C), and the number of colonies were counted
(D). Values are means 6 SEM from three independent experiments. Means with different superscripts are significantly different by ANOVA followed by
Scheffe ´’s test (p , 0.05).
doi:10.1371/journal.pmed.0050094.g003
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signiﬁcantly down-regulated, suggesting speciﬁc deactivation
of the IFN/STAT1 pathway in the rapidly growing vegf 59-
tumors.
STAT1 Expression and Responsiveness to IFNs
To conﬁrm that the vegf mRNA 59UTR selectively deacti-
vated the IFN-dependent pathway in vitro, we measured the
levels of stat1 mRNA and its protein in each stable clone by
Figure 4. Tumor Formation of HCT116 Cells Stably Expressing the vegf 59UTR RNA In Vivo
(A and B) In vivo tumorigenesis in xenografts of stable transfectants. Typical examples of growing tumors on day 28 are shown in (A). Tumor growth
was assessed up to 28 d after inoculation, and tumor volume (mm
3) was calculated by the formula (L3W
230.5). Time-dependent changes in tumor
masses are shown in (B). Values are means 6 SEM from six independent experiments. There were no significant differences between vegf 59-G3 and -G5
or among YFP-G11, vegf 59mut-D5, and vegf 59mut-E4 tumors. #, significantly different compared to YFP-G11, vegf 59mut-D5, and vegf 59mut-E4 tumors
at each time point (p , 0.05 by ANOVA and Scheffe ´’s test).
(C) Immunohistochemistry of the xenografts. On day 28 after inoculation, the growing tumors of vegf 59-G3 and vegf 59mut-D5 were subjected to
hematoxylin and eosin (HE) staining, immunohistochemistry using a mouse monoclonal Ab against BrdU or CD31, or TUNEL staining. Bars indicate 100
lm in the left photograph in each panel, and 50 lm in the right photograph in each panel.
(D) Enhanced proliferation and suppressed apoptosis in the vegf 59UTR-expressing tumors. Proliferation was assessed by calculating the percentages of
BrdU-incorporating cells (left panel). Apoptosis was evaluated by calculating the percentages of TUNEL-positive cells (right panel). Values are means 6
SEM from five independent experiments. #, Significantly different compared to vegf 59mut-D5 tumors (p , 0.05 by two-tailed Student’s t-test).
doi:10.1371/journal.pmed.0050094.g004
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Similar amounts of stat1 mRNA were observed among all
clones (Figure 5A). Both HCT116/YFP and HCT116/vegf 59mut
cells responded to rhIFNa and up-regulated stat1 mRNA
expression, but this up-regulation was not observed in the
HCT116/vegf 59 clones (Figure 5A). Consistent with these,
induction of STAT1 protein by IFNa was defect in the
HCT116/vegf 59cells (Figure 5B).
STAT1 plays a crucial role in the expression of the majority
of IFN-inducible genes [34]. We therefore tested whether the
HCT116/vegf 59 cells actually showed decreased STAT1-
dependent transcriptional activity. For this purpose, we used
two different STAT1-dependent reporter plasmids encoding
a promoter that either contained ISRE-binding sites (pISRE-
Luc) that mainly respond to IFNa or GAS-binding sites
(pGAS-Luc) that preferentially respond to IFNc. Each stable
clone was transiently transfected with pISRE-Luc or pGAS-
Luc reporter plasmid, and then they were treated with
rhIFNa or rhIFNc for 24 h. In the HCT116/vegf 59 clones,
there was signiﬁcant impairment of the IFNa-stimulated
response of ISRE (Figure 5C) and the IFNc-dependent
response of GAS (Figure 5D) compared to the HCT116/vegf
59mut clones or to the HCT116/YFP cells (Figure 5C and 5D).
We conﬁrmed that the IFN receptors were equally expressed
in all clones tested (FigureS9A). These results suggest that the
IFNa pathway might be more severely impaired than the IFNc
pathway. We also measured the levels of endogenous IFNa, b,
and c mRNAs in each clone by quantitative RT-PCR. There
was no difference in the level of IFNa mRNA in each clone
(Figure S9B). Neither clone expressed detectable amounts of
IFNb or IFNc mRNAs.
We further examined the effects of stable knockdown of
endogenous vegf mRNA on STAT1 expression in HCT116
cells (HCT116/siVEGF). Endogenous vegf mRNA was success-
fully silenced in the HCT116/siVEGF clones (Figure 6A). As
shown in Figure 6B, the basal and the IFNa-stimulated
expression levels of STAT1 were signiﬁcantly increased in the
HCT116/siVEGF clones compared with the control clone
(HCT116/siControl) and parental cells (HCT116). Consistent
with these results, both the basal and the IFNa-stimulated
ISRE-dependent transcriptional activities were increased 2-
to 3-fold in the HCT116/siVEGF clones (Figure 6C).
Impairment of the IFNa-Dependent Anti-apoptotic
Pathway in Growing vegf 59-Tumors
To assess whether the reduced IFN signals were responsible
for the malignant transformation of the HCT116/vegf 59 cells,
we examined the effect of IFNs on 5-FU-induced apoptosis, as
IFNs are known to potentiate the pharmacological action of
5-FU [35]. Treatment with rhIFNa or rhIFNc alone did not
induce apoptosis in any of the clones tested, while both IFNa
and IFNc signiﬁcantly enhanced 5-FU-induced apoptosis in
the HCT116/vegf 59mut cells or the HCT116/YFP cells (Figure
5E and 5F). In contrast, neither IFNa nor IFNc had an effect
in the HCT116/vegf 59 cells.
Finally, we examined whether growing vegf 59-tumors had
impaired responses to IFNa in vivo. We therefore focused on
the effects of rhIFNa on tumor growth. For these experi-
ments, we implanted HCT116/vegf 59 (5 310
6 cells) in the left
ﬂank and either HCT116/YFP (1 3 10
7 cells) or HCT116/vegf
59mut (1 3 10
7 cells) in the right ﬂank of the same animal.
When both tumors reached approximately 40 mm
3 on day 7,
we started to treat the mouse once a day with 5-FU (30 mg/kg
body weight) or with a combination of 5-FU (30 mg/kg body
weight) and rhIFNa (50,000 U). At day 4 in the YFP-tumors
(Figure 7A) or day3 in the vegf 59mut-tumors (Figure 7C) after
the 5-FU treatment, the YFP-tumors and the vegf 59mut-
tumors began to reduce in size, respectively. Simultaneous
treatment with rhIFNa accelerated this reduction and most
tumors disappeared within 7 d. In contrast, the responses of
the vegf 59-tumors to 5-FU and rhIFNa were strikingly
different. Treatment with 5-FU initially and transiently
decreased tumor sizes, but they then began to grow rapidly
from day 4 (Figure 7B). Simultaneous administration of
rhIFNa did not have any effect on tumor growth.
Table 1. Validation of Microarray Data on Selected Genes by Quantitative RT-PCR
Type of Gene Gene Symbol Expression Ratio (/gapdh)
vegf 59 (G5) vegf 59mut (D5) p-Value
Apoptosis-associated genes and growth factors MIA 7.12 6 0.25 2.92 6 0.52 0.002
BCL6 0.80 6 0.08 0.61 6 0.06 n.s.
EGFR 1.39 6 0.07 1.60 6 0.09 n.s.
NRG1 1.48 6 0.44 14.21 6 0.12 ,0.001
PCDC1 1.60 6 1.47 2,136.54 6 160.90 ,0.001
FAS 0.7 6 0.11 2.01 6 0.11 ,0.001
BAX 0.55 6 0.07 1.04 6 0.07 0.009
Interferon-responsive genes XAF1 0.82 6 0.02 10.49 6 1.26 0.002
TRAIL/Apo2L 5.24 6 0.12 84.64 6 14.42 0.005
OAS1 3.42 6 0.43 21.36 6 2.24 0.001
OAS2 0.01 6 0.003 0.99 6 0.22 0.012
IRF1 0.82 6 0.23 2.88 6 0.63 0.037
NMI 4.04 6 1.16 22.68 6 3.43 0.007
ISG20 4.48 6 0.58 23.59 6 3.34 0.005
PML 1.26 6 0.32 4.12 6 1.11 n.s.
STAT1 18.51 6 3.07 54.14 6 6.07 0.005
Values are means 6 SEM, n ¼ 3. Significant difference (p , 0.05) based on two-tailed Student’s t-test. n.s., not significant.
doi:10.1371/journal.pmed.0050094.t001
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In the present study, we show a novel function of the vegf
59UTR in tumor cell survival and growth. Both treatment of
vegf-knockdown HCT116 cells with rhVEGF165 and treatment
of VEGF165-overexpressing HCT 116 cells with a neutralizing
anti-VEGF165 Ab suggest the presence of vegf mRNA-
mediated anti-apoptotic action against anti-cancer drugs (5-
FU, etoposide, and doxorubicin). We determined that the
anti-apoptotic action resided in a 270-nt-long element
between positions nt 475 and nt 745 of the 59 UTR of vegf
mRNA. The 59 UTR could exert the anti-apoptotic action
even in the presence of a protein synthesis inhibitor. These
results suggest that the 59UTR may function as a regulatory
RNA.
To further clarify the potential role of vegf 59UTR RNA, we
established HCT116/vegf 59 and HCT116/vegf 59mut clones.
HCT116/vegf 59 cells, but not HCT116/vegf 59mut cells, showed
anchorage-independent growth in vitro and rapidly grew
when implanted in athymic nude mice, indicating that vegf
mRNA 59UTR facilitates tumor progression. The rapid
growth observed in the vegf 59-tumors might be due to the
acquisition of resistance to apoptosis (the process that
eliminates defective cells), which contributes to tumor
development and resistance to drug therapy. Microarray
and quantitative RT-PCR analyses demonstrated that ex-
pression of pro-apoptotic genes (fas, pdcd1, nrg1, and bax) and
an anti-apoptotic gene (mia) was up-regulated and markedly
down-regulated, respectively, in the rapidly growing vegf 59-
tumors. In addition, microarray analysis also showed that the
expression of cell growth-promoting genes (cxcl1, cxcl2, cxcr4,
mia1, and fgf-19) was up-regulated in the rapidly growing vegf
59-tumors.
The combination of both dysregulated cell proliferation
and suppressed cell death are required for neoplastic
progression [36]. In addition, survival and growth under
Table 2. List of IFN-Responsive Genes Selectively Down-Regulated in vegf 59UTR-Overexpressing Cells
Gene Symbol Genbank Accession Number Gene Name Fold Change
GBP1 NM_002053 Guanylate binding protein 1, interferon-inducible, 67 kDa 0.03
IFIT2 NM_001547 Interferon-induced protein with tetratricopeptide repeats 2 0.06
OASL NM_003733 29-59-oligoadenylate synthetase-like 0.09
IL28A NM_172138 Interleukin 28A (interferon, lambda 2) 0.1
XAF-1 NM_017523 XIAP associated factor-1 0.11
TRAIL/Apo2L NM_003810 Tumor necrosis factor (ligand) superfamily, member 10 0.12
IL29 NM_172140 Interleukin 29 (interferon, lambda 1) 0.12
TLR3 NM_003265 Toll-like receptor 3 0.13
OAS2 NM_016817 29-59-oligoadenylate synthetase 2, 69/71 kDa 0.13
IFI44L NM_006820 Interferon-induced protein 44-like 0.18
IFIT3 NM_001549 Interferon-induced protein with tetratricopeptide repeats 3 0.18
IFI44 NM_006417 Interferon-induced protein 44 0.19
IFIT1 NM_001548 Interferon-induced protein with tetratricopeptide repeats 1 0.19
IFI35 NM_005533 Interferon-induced protein 35 0.2
NMI NM_004688 N-myc (and STAT) interactor 0.23
CD47 NM_198793 CD47 antigen 0.27
IFITM1 NM_003641 Interferon-induced transmembrane protein 1 (9–27) 0.28
FAS NM_000043 Fas (TNF receptor superfamily, member 6) 0.29
ISG20 NM_002201 Interferon-stimulated exonuclease gene 20 kDa 0.29
OAS1 NM_002534 29,59-oligoadenylate synthetase 1, 40/46 kDa 0.32
IFI16 AK094968 Interferon, gamma-inducible protein 16 0.34
IFIH1 NM_022168 Interferon induced with helicase C domain 1 0.35
Galectin 9 NM_009587 Lectin, galactoside-binding, soluble, 9 (galectin 9) 0.35
THSD4 NM_024817 thrombospondin, type I, domain containing 4 0.37
IRF1 NM_002198 Interferon regulatory factor 1 0.37
PML NM_033238 Promyelocytic leukemia 0.38
MYD88 NM_002468 Myeloid differentiation primary response gene (88) 0.39
IFITM2 NM_006435 Interferon-induced transmembrane protein 2 (1–8D) 0.4
TAP1 NM_000593 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 0.41
PLSCR1 NM_021105 Phospholipid scramblase 1 0.41
IFITM3 NM_021034 Interferon-induced transmembrane protein 3 (1–8U) 0.43
HLA-G M90686 HLA-G histocompatibility antigen, class I, G 0.43
IFI6 NM_022873 Interferon, alpha-inducible protein 6 0.43
SP110 NM_004510 SP110 nuclear body protein 0.43
ISG20L1 NM_022767 Interferon-stimulated exonuclease gene 20 kDa-like 1 0.44
MMP2 NM_004530 Matrix metallopeptidase 2 0.46
C1R NM_001733 Complement component 1, r subcomponent 0.46
IFIT5 NM_012420 Interferon-induced protein with tetratricopeptide repeats 5 0.47
HLA-C BC008457 Major histocompatibility complex, class I, C 0.47
HLA-A NM_002116 Major histocompatibility complex, class I, A 0.47
B2M NM_004048 Beta-2-microglobulin 0.48
STAT1 NM_007315 Signal transducer and activator of transcription 1, 91 kDa 0.49
IFI30 NM_006332 Interferon, gamma-inducible protein 30 0.49
doi:10.1371/journal.pmed.0050094.t002
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progression [37]. This anchorage-independent property of
tumor cells correlates with their in vivo oncogenic potential.
Thus, we consider that the vegf 59UTR may increase the ability
not only to suppress apoptosis but also to survive and grow in
an anchorage-independent manner, resulting in the accel-
eration of tumor formation.
The precise sequence and structure of the 59UTR of vegf
mRNA as well as the molecular target(s) that interact with the
RNA remain to be elucidated. However, it seems likely that
such a profound change in cell function induced by RNA
would require a global change of gene expression in cells. Our
results support this notion by showing that the vegf mRNA
59UTR modulated expression of numerous genes. One of the
striking ﬁndings is that many of the down-regulated genes
belong to a set of IFN-inducible genes, including stat1.
Since it is reported that IFN down-regulates IRES-depend-
ent translation of distinct mRNAs [38], overexpression of the
IRES-containing 59UTR might attenuate the IFN signal,
leading to the down-regulation of IFN-inducible genes. We
therefore tested whether IFNa affected IRES activity of c-myc,
fgf-2,o rbip using a bicistronic luciferase assay system (Figure
Figure 5. Impaired Responses to IFNs in the vegf 59UTR-Expressing Clones
(A and B) Repression of stat1 mRNA and its protein expression in the vegf 59UTR-expressing cells. Total RNA or whole cell extracts were prepared from
the indicated clones before and 24 h after treatment with 500 U/ml rhIFNa. Levels of stat1 mRNA were measured using quantitative RT-PCR (A). Values
were normalized for the amount of gapdh mRNA (means 6 SEM, n ¼ 4). Means with different superscripts are significantly different by ANOVA and
Scheffe ´’s test (p , 0.05). Amounts of STAT1a (91 kDa) and STAT1b (84 kDa) isoforms were measured by Western blot analysis using an anti-STAT1 Ab (B,
upper panel). The levels of b-actin are shown as a loading control (B, lower panel).
(C and D) Suppression of IFN-mediated transactivation activities in the vegf 59UTR-expressing cells. Each stable transfectant was transiently
cotransfected with pTK-Renilla (as a monitor for transfection efficiency) and with a luciferase reporter plasmid containing ISRE sequence (C) or GAS
sequence (D). Twenty-four hours after transfection, the cells were treated with 500 U/ml rhIFNa (C) or 500 U/ml rhIFNc (D) for 24 h. The luciferase
activity of each construct was calculated as LucF/LucR activity. Results are expressed as fold changes compared to untreated cells. Means with different
superscripts are significantly different by ANOVA and Scheffe ´’s test (p , 0.05).
(E) Resistance to 5-FU and IFNa in the vegf 59UTR-expressing cells. Stable transfectants were untreated or treated with 500 U/ml rhIFNa,8 0lM 5-FU, or
80 lM 5-FU plus 500 U/ml rhIFNa for 48 h. Percentages of apoptotic cells were calculated by the TUNEL-staining method. Values are means 6 SEM, n¼
4. Means with different superscripts are significantly different by ANOVA and Scheffe ´’s test (p , 0.05).
(F) Resistance to 5-FU and IFNc in the vegf 59UTR-expressing cells. As in (E), but 500 U/ml rhIFNc was used instead of 500 U/ml rhIFNa. Values are means
6 SEM, n ¼ 4. Means with different superscripts are significantly different by ANOVA and Scheffe ´’s test (p , 0.05).
doi:10.1371/journal.pmed.0050094.g005
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Tumor Progression by vegf mRNAS7A) in our experimental conditions, and found that IFNa
did not modify at least these IRES activities (Figure S7C). At
the same time, we also conﬁrmed that IFNa signaling,
estimated using the ISRE-dependent transcription reporter
assay, was not inhibited in the cells overexpressing bip, c-myc,
or fgf-2 59UTR, nor was it inhibited in the cells overexpressing
the pdgf-b 59UTR that have no IRES activity (Figure S7D).
Although these results suggest that the suppression of IFN
signaling may be speciﬁc for the vegf 59UTR, further studies
are needed to clarify the molecular mechanism for the
suppression.
The IFNs/STAT1 signal is one of the key pathways for
tumor suppression. Mice with a targeted deletion of the
STAT1 or IFNc receptor develop chemically induced or
spontaneous tumors more rapidly than wild-type mice [39].
Similarly, mouse embryonic ﬁbroblasts deﬁcient in the IFNa
receptor undergo spontaneous malignant transformation,
and the IFNa receptor-deﬁcient mice develop papillomas of
the skin at a high rate when treated with a chemical
carcinogen [40]. In contrast, the reconstitution of STAT1
suppressed the tumorigenicity of STAT1-deﬁcient tumor
cells in vivo, demonstrating that STAT1 acts as an important
tumor suppressor [41]. Indeed, the majority of cancer cell
lines and primary tumors are resistant to IFNs, often through
inhibition of STAT1 expression [42,43]. We propose here that
the vegf mRNA 59UTR negatively regulates expression of
STAT1, leading to suppression of STAT1-dependent tran-
scriptional activities. It has been suggested that STAT1
directly regulates DNA damage-induced apoptosis by tran-
scriptional activation of apoptosis modulating genes, such as
TRAIL, Fas, and XAF-1 [33], all of which were down-regulated
in the vegf 59-tumors (Table 1). Thus, the suppression of
STAT1 may be crucial for malignant transformation of
Figure 6. Enhancement of STAT1 Expression and IFNa Response in the Stable vegf Knockdown Cells
(A) Expression levels of vegf mRNA were measured using quantitative RT-PCR. Values were normalized for the amount of gapdh mRNA (means 6 SEM, n
¼ 4).
(B) Increased expression of STAT1 in the stable vegf knockdown cells. Total proteins were extracted from the indicated clones before and 24 h after
treatment without or with 500 U/ml IFNa. Amounts of STAT1a and STAT1b isoforms were measured by Western blot analysis using an anti-STAT1 Ab.
(C) Enhancement of IFNa-mediated transactivation activity in the stable vegf knockdown cells. Each stable transfectant was transiently cotransfected
with pISRE reporter plasmid and pTK-Renilla. Twenty-four hours after transfection, the cells were treated without or with 500 U/ml rhIFNa for 24 h. The
luciferase activity of each construct was calculated as firefly luciferase/Renilla luciferase activity. Means with different superscripts are significantly
different by ANOVA and Scheffe ´’s test (p , 0.05).
doi:10.1371/journal.pmed.0050094.g006
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Tumor Progression by vegf mRNAHCT116/vegf 59 cells. In fact, the vegf 59-tumors did not
response to IFNa therapy (Figure 7).
Tumor cell growth and survival may require both expres-
sion of VEGF and down-regulation of the IFN pathway.
Consistent with this notion, it is known that IFNa transcrip-
tionally suppresses VEGF expression [44,45]. In contrast, we
suggest here that vegf mRNA may negatively regulate the IFN
signaling pathway by repressing STAT1. This reciprocal
regulation of VEGF and STAT1 is entirely feasible as these
two molecules exert opposing biological functions: VEGF
promotes proliferation, metastasis, and angiogenesis [1–4],
and inhibits apoptosis [1]; in contrast, STAT1 negatively
regulates proliferation, metastasis, and angiogenesis [41,46],
and promotes apoptosis [33,47]. Tumor cells abundantly
expressing vegf mRNA [1,48,49] may use this negative
regulatory mechanism to gain advantages of growth and
survival to escape from the IFN-mediated anti-tumor
machinery. Indeed, we found here that stable knockdown of
endogenous vegf mRNA by siRNA increased STAT1 expres-
sion.
At present, the precise mechanisms for the vegf 59UTR-
mediated anti-apoptotic action are still unknown. However,
our preliminary experiments showed that the vegf 59UTR
RNA might interact with double-stranded RNA-activated
protein kinase (PKR) protein in the cells expressing the full-
length vegf mRNA or the vegf 59UTR RNA, which were
examined by the pull-down assay using an antisense oligonu-
cleotide probe speciﬁc for the vegf 59UTR sequence (unpub-
lished data). It is reported that PKR binds several structured
UTRs of mRNA, such as the 59UTR of ifn-c mRNA [50], the
39UTR of a-tropomyosin mRNA [51], and the 39UTR of tnf-a
mRNA [52]. PKR associates with tumor suppressor, such as
IRF-1 and p53 [53] and induces apoptosis. Our preliminary
data suggest that the vegf 59UTR might interact with PKR and
lead to suppression of PKR-mediated apoptotic pathway.
However, this is still an unproven hypothesis, and further
experiments are being carried out in our laboratory.
Recent studies have revealed that a large number of non-
coding RNAs play a critical role in tumorigenesis [17]. Our
ﬁndings support the concept originally put forward by Blau
and colleagues [18,54] that non-coding regions of mRNAs can
act as RNA regulators for tumor malignancy. There is
increasing evidence that the UTR of certain mRNAs
signiﬁcantly suppresses the tumorigenic properties of cancer
cells both in vitro and in vivo. The 39UTR of a-tropomyosin
mRNA suppresses the proliferation, invasion, and destruction
of muscle tissues characteristic of rhabdomyosarcoma cells
[18]. The 39UTR of ribonucleotide reductase, a key rate-limiting
enzyme in DNA synthesis, and the 39UTR of prohibitin,a n
inhibitor of cell proliferation, signiﬁcantly suppress the
tumorigenic properties and metastatic phenotype of trans-
formed ﬁbroblasts and MCF7 cells [19,20]. In addition, the
59UTR of the human c-myc P0 transcript suppresses the
malignant phenotype of human breast cancer cells with
decreased anchorage-independent proliferation, enhanced
susceptibility to programmed cell death, and complete loss of
the ability to form tumors in the intact animal [21]. To the
Figure 7. Effects of IFNa Treatment on Growth of Xenograft Tumors
An athymic nude mouse was implanted subcutaneously with the vegf 59-G5 clone (5 3 10
6 cells) in the right flank (B) and the YFP-G11(A) or the vegf
59mut-D5 clone (C) (1310
7 cells) in the left flank. On day 7 when tumors had grown to be palpable, the mouse was intraperitoneally injected with 5-FU
(30 mg/kg body weight), or 5-FU (30 mg/kg body weight) plus rhIFNa (50,000 U) once a day. Time-dependent changes in tumor masses were measured
as described in the legend to Figure 4. Values are means 6 SEM, n¼4. #, Significantly different compared to 5-FU-treated tumors at each time point (p ,
0.05 by two-tailed Student’s t-test). A photograph showing a typical tumor growing on day 7 of IFN-treatment is inserted in each figure.
doi:10.1371/journal.pmed.0050094.g007
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Tumor Progression by vegf mRNAbest of our knowledge, the 59UTR vegf mRNA is the ﬁrst
example of tumor-promoting UTR RNA.
VEGF protein is considered to be an important therapeutic
target for cancer treatment, and anti-VEGF strategies are
undergoing clinical evaluation [14]. A number of preclinical
studies have demonstrated that anti-VEGF therapy alone can
suppress the growth of established tumors [55,56]. Unlike
these preclinical studies, anti-VEGF-speciﬁc Ab (bevacizu-
mab) alone has not been shown to increase survival in lung
and colorectal cancer patients [14]. The combined use of
bevacizumab with standard chemotherapy increased overall
survival in metastatic colorectal cancer [57], but did not
improve the clinical outcome in metastatic breast cancers in
previously treated patients [58]. Furthermore, the combina-
tion of the VEGF receptor tyrosine kinase inhibitor,
vatalanib, with chemotherapy did not show an increased
survival rate in metastatic colorectal cancer patients [59]. Our
ﬁnding that the novel intrinsic tumor-promoting activity
presents in the vegf mRNA might explain, at least in part, the
inconsistencies of outcome associated with VEGF-VEGFR
strategies. The present study suggests that both vegf mRNA
and VEGF protein may synergistically promote the malig-
nancy of tumor cells. Thus anti-vegf transcript therapy, such
as siRNA-based gene silencing, in combination with anti-
VEGF therapy might provide optimal anti-tumor effects,
including inhibition of angiogenesis, blockade of tumor cell
survival, and enhanced sensitivity to radiation and drug
therapies.
Supporting Information
Figure S1. Effect of vegf Transcript on Susceptibility to Anti-cancer
Drugs
(A and B) Knockdown of vegf transcript increases apoptosis induced
by etoposide and doxorubicin. Cells untransfected ( ) or transfected
with the indicated plasmids for 24 h were treated with 3 lM etoposide
(A), 20 nM doxorubicin (B), or rhVEGF protein (1 or 2 ng/ml)
combined with each drug for 40 h. Apoptosis was evaluated by
calculating the percentages of TUNEL-positive cells. Values are
means 6 standard error of the mean (SEM) from four independent
experiments. Means with different superscripts are signiﬁcantly
different by ANOVA followed by Scheffe ´’s test (p , 0.05).
(C and D) Overexpression of vegf transcript induces resistance to anti-
cancer drugs. Cells untransfected ( ) or transfected with the indicated
constructs for 24 h were treated with 20 lM etoposide (C) or 340 nM
doxorubicin (D) for 48 h, and then apoptosis was evaluated by the
TUNEL method. Values are means 6 SEM from three independent
experiments. Means with different superscripts are signiﬁcantly
different by ANOVA followed by Scheffe ´’s test (p , 0.05).
Found at doi:10.1371/journal.pmed.0050094.sg001 (1.1 MB TIF)
Figure S2. Expression of Transfected Construct Transcripts and
Their Proteins
(A) Levels of transfected vegf mRNAs and their proteins were
measured by Northern and Western analyses, respectively. Northern
hybridization of vegf mRNA was performed using a cDNA probe
speciﬁc for vegf ORF. Levels of HA-tagged VEGF and b-actin proteins
were measured using a rabbit polyclonal anti-HA Ab and a mouse
monoclonal Ab against b-actin, respectively.
(B) Levels of transfected vegf 59UTR-CAT constructs were analyzed by
Northern blot analysis using a cDNA probe speciﬁc for cat. Levels of
L-VEGF protein were measured by Western blotting using a rabbit
polyclonal anti-L-VEGF Ab.
Found at doi:10.1371/journal.pmed.0050094.sg002 (1.8 MB TIF)
Figure S3. Effects of vegf 59UTR on 5-FU-Induced Apoptosis
(A–C) HCT116 cells transfected with the indicated plasmids for 24 h
were treated with 80 lM 5-FU for 40 h. Cells undergoing apoptosis
were detected by the TUNEL method (A and B) or the APOPercent-
age assay (C). Values are means 6 SEM, n ¼ 4. Means with different
superscripts are signiﬁcantly different by ANOVA and Scheffe ´’s test
(p , 0.05).
(D) Twenty-four hours after transfection with the indicated plasmids,
the cells were treated with 80 lM of 5-FU or 80 lM 5-FU plus 5 lg/ml
of the monoclonal mouse anti-human VEGF165-neutralizing Ab (þ
Ab) for 24 h. Then, apoptosis was evaluated by the caspase 3/7 activity.
Means with different superscripts are signiﬁcantly different by
ANOVA followed by Scheffe ´’s test (p , 0.05). vegf mRNA wt, wild-
type full-length vegf165 mRNA without mutation in sequence
encoding signal peptide.
Found at doi:10.1371/journal.pmed.0050094.sg003 (5.5 MB TIF)
Figure S4. Effects of Several 59UTR RNAs on Resistance to 5-FU in
HCT116 Cells
Cells transfected with the indicated plasmid for 24 h were treated
with 80 lM 5-FU for 40 h. Percentages of apoptotic cells were
calculated. Values are means 6 SEM, n ¼ 4. Means with different
superscripts are signiﬁcantly different by ANOVA and Scheffe ´’s test
(p , 0.05).
Found at doi:10.1371/journal.pmed.0050094.sg004 (919 KB TIF)
Figure S5. Prediction of RNA Secondary Structures
The sequences of vegf 59UTR (A) and mutated vegf 59UTR (B) were
analyzed using the mfold algorithm 3.2 of Zuker.
A circle shown in (A) indicates the stem-loop located in the region
that is required for the vegf 59UTR function.
Found at doi:10.1371/journal.pmed.0050094.sg005 (2.6 MB TIF)
Figure S6. Effects of vegf 59UTR RNA on Resistance to 5-FU in RKO,
HEK293, and AGS Cells
(A) The levels of mRNAs for VEGF receptors (vegfr1, vegfr2, nrp1, and
nrp2) in the indicated cell lines were analyzed by RT-PCR.
(B–D) RKO cells (B), HEK293 cells (C), and AGS cells (D) were
transfected with the indicated constructs for 24 h. The cells were
untreated or treated with 150 lM 5-FU for 48 h. In the case of cells
transfected with the plasmid expressing full-length vegf mRNA, the
cells were treated with 150 lM 5-FU plus 5 lg/ml of a monoclonal
anti-human VEGF165-neutralizing Ab (þAb) for 48 h. Then, apoptosis
was evaluated by the TUNEL method. Values are means 6 SEM from
three independent experiments. Means with different superscripts
are signiﬁcantly different by ANOVA followed by Scheffe ´’s test (p ,
0.05).
Found at doi:10.1371/journal.pmed.0050094.sg006 (1.4 MB TIF)
Figure S7. Effect of the vegf 59UTR RNA or IFNa on Cellular IRES
Activities
(A) Schematic diagram of bicistronic plasmid. The bicistronic cassette
expresses the LucR in a cap-dependent manner and LucF in an IRES-
dependent manner. Each IRES or hairpin control is located between
the two cistrons.
(B) HCT116 cells were cotransfected with 0.5 lg of the indicated vegf
59UTR-expressing plasmid and 0.25 lg of bicistronic plasmid
containing the indicated 59UTR. The each IRES activity was
calculated as LucF/LucR activity.
(C) IFNa has no effect on cellular IRES activity. HCT116 cells were
transfected with the indicated bicistronic plasmid for 24 h, then they
were treated with 500 U/ml IFNa for 24 h. The luciferase activity of
each construct was calculated as described in (B).
(D) Overexpression of IRES-containing 59UTR has no effect on IFNa
signaling. HCT116 cells were cotransfected with the indicated 59UTR-
CAT-expressing plasmid and luciferase reporter plasmid containing
ISRE sequence. Twenty-four hours after transfection, the cells were
treated with 500 U/ml rhIFNa for 24 h. The luciferase activity of each
construct was measured and calculated as LucF/LucR activity.
Found at doi:10.1371/journal.pmed.0050094.sg007 (994 KB TIF)
Figure S8. Expression Levels of Transfected mRNA and Endogenous
vegf mRNA, and Secretion Levels of VEGF by Stable Transfectants
(A) Levels of exogenous vegf 59 UTR-yfp mRNA (upper panel),
endogenous vegf mRNA (middle panel), and gapdh mRNA (loading
control, lower panel) were measured by Northern hybridization using
probes speciﬁc for yfp, vegf ORF, and gapdh, respectively. The
transfectants expressed similar levels of chimeric RNA. The stable
transfections of different chimeric mRNAs did not signiﬁcantly
changes the expression of endogenous vegf mRNA.
(B) Amounts of VEGF165 secreted into the culture medium for 24 h
were measured by ELISA assay. Values are means 6 SEM, n ¼ 4.
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Tumor Progression by vegf mRNAFound at doi:10.1371/journal.pmed.0050094.sg008 (1.5 MB TIF)
Figure S9. Expression of IFN Receptors and IFN-a2 mRNAs in Stable
Clones
(A) The mRNA levels of IFN receptors (ifnar1, ifnar2, ifngr1, and ifngr2)
and b-actin in the transfectants were measured by RT-PCR. Each
stable clone showed similar levels of expression of ifnr mRNAs.
(B) The levels of ifna2 mRNA in each clone were measured by
quantitative RT-PCR.
Found at doi:10.1371/journal.pmed.0050094.sg009 (1.6 MB TIF)
Figure S10. Conﬁrmation of the Speciﬁcity of Antibody Reactivity
Cell extracts were prepared from HCT116 cells treated with 500 U/ml
IFN-a (A), or transfected with plasmid expressing L-VEGF (B), or HA-
tagged VEGF (C). After each extract was either untreated ( )o r
treated (þ) with antigen peptide, as described in the Methods section,
they were subjected to Western blotting.
Found at doi:10.1371/journal.pmed.0050094.sg010 (1.1 MB TIF)
Table S1. List of All Genes Selectively Up-regulated in vegf 59UTR-
Expressing Tumors
Found at doi:10.1371/journal.pmed.0050094.st001 (462 KB DOC)
Table S2. List of All Genes Selectively Down-regulated in vegf 59UTR-
Expressing Tumors
Found at doi:10.1371/journal.pmed.0050094.st002 (365 KB DOC)
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/) accession numbers of
the genes discussed in this paper are vegf-a (NM_001025368), mia
(NM_006533), bcl6 (NM_138931), egfr (X00588), nrg1 (NM_013962),
pdcd1 (NM_005018), fas (NM_000043), and bax (NM_138764).
The Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.
gov/geo/) raw chip data ﬁles discussed in this paper are accession
number GSE8888.
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Tumor Progression by vegf mRNAEditors’ Summary
Background Normally, throughout life, cell division (which produces
new cells) and cell death are carefully balanced to keep the body in good
working order. But sometimes cells acquire changes (mutations) in their
genetic material that allow them to divide uncontrollably to form
cancers—disorganized masses of cells. When a cancer is small, it uses the
body’s existing blood supply to get the oxygen and nutrients it needs for
its growth and survival. But, when it gets bigger, it has to develop its
own blood supply. This process is called angiogenesis. It involves the
release by the cancer cells of proteins called growth factors that bind to
other proteins (receptors) on the surface of endothelial cells (the cells
lining blood vessels). The receptors then send signals into the
endothelial cells that tell them to make new blood vessels. One
important angiogenic growth factor is ‘‘vascular endothelial growth
factor’’ (VEGF). Tumors that make large amounts of VEGF tend to be
more abnormal and more aggressive than those that make less VEGF. In
addition, high levels of VEGF in the blood are often associated with poor
responses to chemotherapy, drug regimens designed to kill cancer cells.
Why Was This Study Done? Because VEGF is a key regulator of tumor
development, several anti-VEGF therapies—drugs that target VEGF and
its receptors—have been developed. These therapies strongly suppress
the growth of tumor cells in the laboratory and in animals but, when
used alone, are no better at increasing the survival times of patients with
cancer than standard chemotherapy. Scientists are now looking for an
explanation for this disappointing result. Like all proteins, cells make
VEGF by ‘‘transcribing’’ its DNA blueprint into an mRNA copy (vegf
mRNA), the coding region of which is ‘‘translated’’ into the VEGF protein.
Other, ‘‘noncoding’’ regions of vegf mRNA control when and where VEGF
is made. Scientists have recently discovered that the noncoding regions
of some mRNAs suppress tumor development. In this study, therefore,
the researchers investigate whether vegf mRNA has an unrecognized
function in tumor cells that could explain the disappointing clinical
results of anti-VEGF therapeutics.
What Did the Researchers Do and Find? The researchers first used a
technique called small interfering (si) RNA knockdown to stop VEGF
expression in human colon cancer cells growing in dishes. siRNAs are
short RNAs that bind to and destroy specific mRNAs in cells, thereby
preventing the translation of those mRNAs into proteins. The treatment
of human colon cancer cells with vegf-targeting siRNAs made the cells
more sensitive to chemotherapy-induced apoptosis (a type of cell death).
This sensitivity was only partly reversed by adding VEGF to the cells. By
contrast, cancer cells engineered to make more vegf mRNA had
increased resistance to chemotherapy-induced apoptosis. Treatment of
these cells with an antibody that inhibited VEGF function did not
completely block this resistance. Together, these results suggest that
both vegf mRNA and VEGF protein have anti-apoptotic effects. The
researchers show that the anti-apoptotic activity of vegf mRNA requires a
noncoding part of the mRNA called the 59 UTR, and that whereas human
colon cancer cells expressing this 59 UTR form tumors in mice, cells
expressing a mutated 59 UTR do not. Finally, they report that the
expression of several pro-apoptotic genes and of an anti-tumor pathway
known as the interferon/STAT1 tumor suppression pathway is down-
regulated in tumors that express the vegf 59 UTR.
What Do These Findings Mean? These findings suggest that some
cancer cells have a survival system that is regulated by vegf mRNA and
are the first to show that a 59UTR of mRNA can promote tumor growth.
They indicate that VEGF and its mRNA work together to promote their
development and to increase their resistance to chemotherapy drugs.
They suggest that combining therapies that prevent the production of
vegf mRNA (for example, siRNA-based gene silencing) with therapies that
block the function of VEGF might improve survival times for patients
whose tumors overexpress VEGF.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050094.
  This study is discussed further in a PLoS Medicine Perspective by
Hughes and Jones
  The US National Cancer Institute provides information about all
aspects of cancer, including information on angiogenesis, and on
bevacizumab, an anti-VEGF therapeutic (in English and Spanish)
  CancerQuest, from Emory University, provides information on all
aspects of cancer, including angiogenesis (in several languages)
  Cancer Research UK also provides basic information about what
causes cancers and how they develop, grow, and spread, including
information about angiogenesis
  Wikipedia has pages on VEGF and on siRNA (note that Wikipedia is a
free online encyclopedia that anyone can edit; available in several
languages)
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